Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study
Authors
Keywords
-
Journal
Lancet Haematology
Volume 9, Issue 10, Pages e766-e775
Publisher
Elsevier BV
Online
2022-09-07
DOI
10.1016/s2352-3026(22)00225-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-World Use of Tisagenlecleucel in Infant Acute Lymphoblastic Leukemia
- (2022) Amy Moskop et al. Blood Advances
- Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
- (2022) Adam Lamble et al. Blood Advances
- Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
- (2021) Marie-Emilie Dourthe et al. LEUKEMIA
- Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium
- (2021) Swantje Buchmann et al. BLOOD
- Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy
- (2021) Allison Barz Leahy et al. BLOOD
- A Phase 2 Study to Test the Feasibility, Safety and Efficacy of the Addition of Blinatumomab to the Interfant06 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network
- (2021) Inge M. Van Der Sluis et al. BLOOD
- Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report
- (2021) Liora M. Schultz et al. JOURNAL OF CLINICAL ONCOLOGY
- Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
- (2021) Regina M. Myers et al. JOURNAL OF CLINICAL ONCOLOGY
- Blinatumomab for Infant Acute Lymphoblastic Leukaemia
- (2020) Katherine Clesham et al. BLOOD
- A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial
- (2020) Daisuke Tomizawa et al. BLOOD
- Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
- (2019) Rob Pieters et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
- (2019) Colleen Annesley et al. BLOOD
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol
- (2015) E M C Driessen et al. LEUKEMIA
- Lineage switch in childhood acute leukemia: An unusual event with poor outcome
- (2012) Jorge G. Rossi et al. AMERICAN JOURNAL OF HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started